|
Sex
|
Male
|
27 (73.0%)
|
|
Female
|
10 (27.0%)
|
|
Age (year)
| |
63.5 ± 9.1
|
|
Weight(kg)
| |
63.14 ± 11.03
|
|
Primary disease
|
Glomerulonephritis
|
15 (40.5%)
|
|
Diabetic nephropathy
|
15 (40.5%)
|
|
Renal failure, unspecified
|
1 (2.7%)
|
|
Other
|
6 (16.2%)
|
|
Type of dialysis solution
|
Dextrose and icodextrin solutions, or icodextrin solution alone
|
17 (45.9%)
|
|
Dextrose solution
|
20 (54.1%)
|
|
Type of peritoneal dialysis
|
CCPD (with APD)
|
13 (35.1%)
|
|
CAPD (without APD)
|
24 (64.9%)
|
|
Duration of peritoneal dialysis (year)
| |
2.30 ± 2.33
|
|
With anamnesis
| |
20 (54.1%)
|
|
With complications
| |
37 (100.0%)
|
|
Duration of itching (year)
| |
1.76 ± 2.20
|
|
Mean VAS score in week 2 in the pretreatment period observation (mm) (the larger of the score upon rising or before bed)
|
77.22 ± 11.46
|
|
Mean itch score based on Shiratori’s severity criteria in week 2 in the pretreatment period observation (the larger of the score upon rising or before bed)
|
3.11 ± 0.37
|
|
Pruritus treatments used within 1 year before the informed consent acquisition date
|
|
Oral drug
|
Antihistamines or antiallergics
|
37 (100.0%)
|
|
Steroid
|
0 (0.0%)
|
|
Other
|
0 (0.0%)
|
|
Total
|
37 (100.0%)
|
|
Topical product
|
Antihistamines or antiallergics
|
11 (29.7%)
|
|
Steroid
|
12 (32.4%)
|
|
Moisturizing agents
|
27 (73.0%)
|
|
Other
|
11 (29.7%)
|
|
Total
|
37 (100.0%)
|
|
Injection product
|
Antihistamines or antiallergics
|
0 (0.0%)
|
|
Steroid
|
0 (0.0%)
|
|
Stronger neo-minophagen C
|
0 (0.0%)
|
|
Other
|
0 (0.0%)
|
|
Total
|
0 (0.0%)
|
|
Pruritus treatments used during clinical trial
| |
|
Oral drug
|
Antihistamines or antiallergics
|
34 (91.9%)
|
|
Steroid
|
0 (0.0%)
|
|
Other
|
0 (0.0%)
|
|
Total
|
34 (91.9%)
|
|
Topical product
|
Antihistamines or antiallergics
|
7 (18.9%)
|
|
Steroid
|
11 (29.7%)
|
|
Moisturizing agents
|
24 (64.9%)
|
|
Other
|
12 (32.4%)
|
|
Total
|
37 (100.0%)
|
|
Injection product
|
Antihistamines or antiallergics
|
0 (0.0%)
|
|
Steroid
|
0 (0.0%)
|
|
Stronger neo-minophagen C
|
1 (2.7%)
|
|
Other
|
0 (0.0%)
|
|
Total
|
1 (2.7%)
|
|
Pruritus-related factors in CKD patients
|
|
Complications (overlapping)
|
Hyperphosphatemia
|
28 (75.7%)
|
|
Secondary hyperparathyroidism
|
27 (73.0%)
|
|
Asteatosis
|
3 (8.1%)
|
|
Hypocalcemia
|
1 (2.7%)
|
|
Xeroderma
|
1 (2.7%)
|
|
Immunodeficiency
|
1 (2.7%)
|
|
Laboratory value (pretreatment value)
|
Mean plasma hemoglobin (g/dL; ± SD)
|
10.58 ± 1.33
|
|
Mean plasma eosinophils (%; ± SD)
|
7.43 ± 6.54
|
|
Mean serum albumin (g/dL; ± SD)
|
3.49 ± 0.40
|
|
Mean plasma hematocrit (%; ± SD)
|
31.98 ± 4.22
|
|
Mean serum urea nitrogen (mg/dL; ± SD)
|
56.2 ± 14.1
|
|
Mean serum creatinine (mg/dL; ± SD)
|
9.953 ± 3.179
|
|
Mean serum phosphorus (mg/dL; ± SD)
|
5.18 ± 1.10
|
|
Mean serum calcium (mg/dL; ± SD)
|
8.85 ± 0.89
|
